IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease

ChangeBridge: Patent Grants - Peptides (C07K)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.

View original document View source feed page

What changed

The USPTO issued a patent grant to Viridian Therapeutics, Inc. for IGF-1R antibody compositions useful in treating thyroid eye disease, including reducing proptosis and Clinical Activity Score. The patent contains 23 claims covering antibodies targeting IGF-1R and pharmaceutical compositions for therapeutic use.

Pharmaceutical companies and biotech firms developing IGF-1R-targeted therapies for ophthalmic conditions should conduct freedom-to-operate analyses and consider potential licensing needs. Healthcare providers administering TED treatments should be aware of this newly granted intellectual property covering IGF-1R inhibition therapies.

What to do next

Monitor patent portfolio for freedom-to-operate considerations
Review competitive landscape for IGF-1R targeting therapies
Assess licensing opportunities if developing similar treatments

Source document (simplified)

← USPTO Patent Grants

Compositions and methods for treatment of thyroid eye disease

Grant US12595309B2 Kind: B2 Apr 07, 2026

Assignee

Viridian Therapeutics, Inc.

Inventors

Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao

Abstract

Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS), by inhibiting the activity of IGF-1R with such antibodies and compositions.